SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (268)5/25/1999 8:18:00 PM
From: Pseudo Biologist  Read Replies (3) | Respond to of 1475
 
Rick, from the release <<AMEVIVE(TM) (Recombinantly Engineered LFA-3/IgG1 Human Fusion Protein)>> i.e. this is *not* an anti-LFA3 antibody, but rather an LFA-3 domain or domains fused to IgG. So, Amevive should be binding to CD2 itself (and to whatever unknown ligands of LFA-3 out there). So, yes your guess makes sense, but I am not sure how it applies to Amevive (do people get paid to come up with these names??).

confused PB


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News